ProteGenix provides a comprehensive suite of antibody discovery platforms to meet diverse research and therapeutic needs: custom hybridoma development, single B cell screening service, and phage display service. We also offer humanized mouse services and phage display service against human libraries for the generation of fully human antibodies. Additionally, we provide custom polyclonal antibody production for projects where this approach is most appropriate.

Yes. Our hybridoma development platform includes a fast-track protocol capable of delivering results in as little as 45 days.

Learn more about our RocketAbs platform

We also give you access to our innovative proprietary libraries, designed to maximize the chances of identifying high-quality binders.

Explore our phage display libraries to find out more

Absolutely. Our team will work closely with you to identify the platform best suited to your specific target and goals. Every project is reviewed by a dedicated PhD-level expert who provides personalized strategic advice, ensuring the selected approach gives you the best possible chances of success.

Complex projects are where we truly excel. Our team has extensive hands-on experience with challenging targets, including membrane proteins, low-immunogenic antigens, and other difficult-to-address molecules. We apply tailored strategies and leverage our full technical expertise to tackle these projects with the same commitment to success as any other.

Timelines vary depending on the complexity of the project and the platform selected. In some cases, lead antibody identification can be achieved in as little as 4 weeks. Your PhD expert will provide a realistic timeline estimate during the initial project review.

Yes, absolutely. We are fully equipped to run simultaneous discovery campaigns across multiple targets, allowing you to accelerate your program without compromise on quality or throughput.

Yes. Every project benefits from a dedicated review by one of our PhD-level experts, who will assess your target, objectives, and constraints to recommend the most appropriate discovery strategy. You are never left to navigate these decisions alone.

Yes, full ownership of all discovered antibody sequences is transferred to you. There are no hidden restrictions or royalties.

We don’t give up easily. Our team is committed to finding the solution you need, and we actively explore alternative strategies before concluding a project. In the rare event that no suitable antibody is identified, we back our work with the strongest guarantees on the market: if we do not deliver your antibody, you do not pay the full service price.

Yes. If an initial strategy does not yield the expected results, we can rapidly pivot to alternative discovery routes. Our broad platform portfolio and experienced team mean that we always have additional options to explore on your behalf.